ES2125198A1 - Asociacion de dosis dija de un inhibidor de la enzima convertidora de angiotensina y de un antagonista de los canales de calcio, procedimiento para su preparacion y utilizacion para el tratamiento de enfermedades cardiovasculares. - Google Patents

Asociacion de dosis dija de un inhibidor de la enzima convertidora de angiotensina y de un antagonista de los canales de calcio, procedimiento para su preparacion y utilizacion para el tratamiento de enfermedades cardiovasculares.

Info

Publication number
ES2125198A1
ES2125198A1 ES09701017A ES9701017A ES2125198A1 ES 2125198 A1 ES2125198 A1 ES 2125198A1 ES 09701017 A ES09701017 A ES 09701017A ES 9701017 A ES9701017 A ES 9701017A ES 2125198 A1 ES2125198 A1 ES 2125198A1
Authority
ES
Spain
Prior art keywords
dose
treatment
agent
angiotensin
fixed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES09701017A
Other languages
English (en)
Other versions
ES2125198B1 (es
Inventor
Soler Pedro Canovas
Duarte Joaquin Anto Delgadillo
Escude Luis Manuel Micheto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ferrer Internacional SA
Original Assignee
Vita Invest SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8299270&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2125198(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vita Invest SA filed Critical Vita Invest SA
Priority to ES009701017A priority Critical patent/ES2125198B1/es
Priority to IL12425398A priority patent/IL124253A/xx
Priority to CZ19981381A priority patent/CZ292616B6/cs
Priority to ZA983806A priority patent/ZA983806B/xx
Priority to NO19982112A priority patent/NO315545B1/no
Priority to SK616-98A priority patent/SK284337B6/sk
Priority to TW087107210A priority patent/TW562679B/zh
Priority to ARP980102163A priority patent/AR011730A1/es
Priority to ES98500119T priority patent/ES2197443T3/es
Priority to PL326246A priority patent/PL192117B1/pl
Priority to DK98500119T priority patent/DK0884054T3/da
Priority to HU9801075A priority patent/HUP9801075A3/hu
Priority to DE69813083T priority patent/DE69813083T2/de
Priority to CA002234899A priority patent/CA2234899C/en
Priority to RU98109345/14A priority patent/RU2182002C2/ru
Priority to AT98500119T priority patent/ATE236653T1/de
Priority to EP98500119A priority patent/EP0884054B9/en
Priority to PT98500119T priority patent/PT884054E/pt
Priority to CNB981098371A priority patent/CN1146418C/zh
Priority to AU65973/98A priority patent/AU735404B2/en
Priority to BR9805597-6A priority patent/BR9805597A/pt
Priority to NZ330447A priority patent/NZ330447A/xx
Priority to TR1998/00847A priority patent/TR199800847A3/tr
Priority to JP13059098A priority patent/JP3576806B2/ja
Publication of ES2125198A1 publication Critical patent/ES2125198A1/es
Publication of ES2125198B1 publication Critical patent/ES2125198B1/es
Application granted granted Critical
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Asociación a dosis fija de un inhibidor de la enzima convertidora de angiotensina y de un antagonista de los canales de calcio, procedimiento para su preparación y su utilización para el tratamiento de enfermedades cardiovasculares. Comprende (a) enalapril o una sal farmacéuticamente aceptable del mismo y (b) nitrendipino o una sal farmacéuticamente aceptable del mismo, que se administra en forma galénica de dosis unitaria. El procedimiento comprende: a) disolver enalapril en agua con una sal inorgánico, b) mezclar el nitrendipino con una fracción de los excipientes disgregantes, agente mojante, diluyente fragmentario, agente aglutinante y diluyente plástico, previamente tamizados, c) granular la mezcla del apartado (b) con la solución obtenida en el apartado (a); (d) secar la masa granulada, (e) incorporar el agente lubricante y la fracción restante de excipientes y homogeneizar el granulado calibrado; (f) comprimir el granulado. Utilización de dicha asociación para la fabricación de un medicamento para el tratamiento de enfermedades del sistema cardiovascular.
ES009701017A 1997-05-13 1997-05-13 Asociacion a dosis fija de un inhibidor de la enzima convertidora de angiotensina y de un antagonista de los canales de calcio, procedimiento para su preparacion y su utilizacion para el tratamiento de enfermees cardiovasculares. Expired - Fee Related ES2125198B1 (es)

Priority Applications (24)

Application Number Priority Date Filing Date Title
ES009701017A ES2125198B1 (es) 1997-05-13 1997-05-13 Asociacion a dosis fija de un inhibidor de la enzima convertidora de angiotensina y de un antagonista de los canales de calcio, procedimiento para su preparacion y su utilizacion para el tratamiento de enfermees cardiovasculares.
IL12425398A IL124253A (en) 1997-05-13 1998-04-28 Fixed-dose combination of an angiotensin-converting enzyme inhibitor and of a calcium channel antagonist and method for preparation and use thereof in the manufacture of a medicament for treatment of cardiovascular illness
CZ19981381A CZ292616B6 (cs) 1997-05-13 1998-05-05 Kombinace fixních dávek inhibitoru enzymu konvertujícího angiotensin a antagonisty vápníkového kanálu, její použití, farmaceutická kompozice na bázi této kombinace a způsob její výroby
ZA983806A ZA983806B (en) 1997-05-13 1998-05-06 Fixed-dose association of an angiotensin-converting enzyme inhibitor and of a calcium channel antagonist method for preparation and use thereof in the treatment of cardiovascular illnesses
NO19982112A NO315545B1 (no) 1997-05-13 1998-05-08 Blanding med bestemt dose, av en angiotensinkonverterende enzyminhibitor ogav en kalsiumkanal antagonist, fremgangsmåte for fremstilling oganvendelse derav ved behandling av kardiovaskul¶re sykdommer
SK616-98A SK284337B6 (sk) 1997-05-13 1998-05-11 Kombinácia fixných dávok inhibítora enzýmu konvertujúceho angiotenzín a antagonistu vápnikového kanálu, jej použitie, farmaceutická kompozícia na báze tejto kombinácie a spôsob jej výroby
TW087107210A TW562679B (en) 1997-05-13 1998-05-11 A pharmaceutical composition for fixed-dose association of an angiotensin-converting enzyme inhibitor and of a calcium channel antagonist, method for preparation and a pharmaceutical composition for the treatment of cardiovascular illnesses
ARP980102163A AR011730A1 (es) 1997-05-13 1998-05-11 UNA FORMA FARMACÉUTICA DE CANTIDADES FIJAS DE UN INIHIBIDOR DE LA ENZIMA CONVERSORA DE ANGIOTENSINA Y DE UN ANTAGONISTA DEL CANAL DE CALCIO , COMPOSICIoN FARMACÉUTICAMENTE ACEPTABLE QUE COMPRENDE DICHA FORMA FARMACÉUTICA , PROCEDIMIENTO PARA LA OBTENCIoN DE DICHA COMPOSICIoN FARMACÉUTICAMENTE ACEPTA
DE69813083T DE69813083T2 (de) 1997-05-13 1998-05-12 Kombination in feste Dosiermenge von Angiotensin-Converting-Enzyme-Hemmern mit Calcium-Kanal Antagonisten zur Behandlung von Herz-Kreislauferkrankungen
PL326246A PL192117B1 (pl) 1997-05-13 1998-05-12 Kompozycja o ustalonej dawce połączonego inhibitora enzymu przekształcającego angiotensynę i antagonisty kanału wapniowego i jej zastosowanie w leczeniu chorób sercowo-naczyniowych
DK98500119T DK0884054T3 (da) 1997-05-13 1998-05-12 Fastdosiskombination af en angiotensin-omdannende enzyminhibitor og en calsiumkanalantagonist til behandling af cardiovaskulære sygdomme
HU9801075A HUP9801075A3 (en) 1997-05-13 1998-05-12 Fixed-dose association of an angiotensinconverting enzyme inhibitor and of a calcium channel antagonist, method for preparation and use thereof in the treatment of cardiovascular illnesses
ES98500119T ES2197443T3 (es) 1997-05-13 1998-05-12 Asociacion a dosis fijas de un inhibidor de la enzima convertidora de angiotensina y de un antagonista de los canales de calcio para el tratamiento de enfermedades cardiovasculares.
CA002234899A CA2234899C (en) 1997-05-13 1998-05-12 Fixed-dose association of an angiotensin-converting enzyme inhibitor and of a calcium channel antagonist, method for preparation and use thereof in the treatment of cardiovascularillnesses
RU98109345/14A RU2182002C2 (ru) 1997-05-13 1998-05-12 Композиция с фиксированной дозой ингибитора ангиотензин-превращающего фермента и антагониста кальциевых каналов, способ ее изготовления и применение для лечения сердечно-сосудистых заболеваний
AT98500119T ATE236653T1 (de) 1997-05-13 1998-05-12 Kombination in feste dosiermenge von angiotensin- converting-enzyme-hemmern mit calcium-kanal antagonisten zur behandlung von herz- kreislauferkrankungen
EP98500119A EP0884054B9 (en) 1997-05-13 1998-05-12 Fixed-dose association of an angiotensin-converting enzyme inhibitor and of a calcium channel antagonist for the treatment of cardiovascular illnesses
PT98500119T PT884054E (pt) 1997-05-13 1998-05-12 Associacao de dose fixa compreendendo um inibidor do enzima conversor da angiotensina e de um antagonista dos canais de calcio para o tratamento de doencas cardiovasculares
CNB981098371A CN1146418C (zh) 1997-05-13 1998-05-12 血管紧张肽转化酶抑制剂和钙通道拮抗剂的定量结合物及其制备方法和在心血管疾病的治疗中的用途
AU65973/98A AU735404B2 (en) 1997-05-13 1998-05-13 Fixed-dose association of an angiotensin-converting enzyme inhibitor and of a calcium channel antagonist
BR9805597-6A BR9805597A (pt) 1997-05-13 1998-05-13 Associação em dose fixa de um inibidor da enzima conversora da angiotensina e de um antagonista dos canais de cálcio, procedimento para sua preparação e sua utilização para o tratamento de enfermidades cardiovasculares.
NZ330447A NZ330447A (en) 1997-05-13 1998-05-13 Angiotensin-converting enzyme inhibitor, enalapril, and the calcium channel antagonist, nitrendipine, in a fixed dose association for the treatment of arterial hypertension and other cardiovascular illnesses
TR1998/00847A TR199800847A3 (tr) 1997-05-13 1998-05-13 Bir anjiyotensin dönüstürücü enzim inhibitörünün sabit doz bilesimi.
JP13059098A JP3576806B2 (ja) 1997-05-13 1998-05-13 アンギオテンシン変換酵素阻害剤とカルシウムチャンネル拮抗剤との固定用量組合せ、製造法、および心血管病の治療におけるその用途

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES009701017A ES2125198B1 (es) 1997-05-13 1997-05-13 Asociacion a dosis fija de un inhibidor de la enzima convertidora de angiotensina y de un antagonista de los canales de calcio, procedimiento para su preparacion y su utilizacion para el tratamiento de enfermees cardiovasculares.

Publications (2)

Publication Number Publication Date
ES2125198A1 true ES2125198A1 (es) 1999-02-16
ES2125198B1 ES2125198B1 (es) 1999-11-16

Family

ID=8299270

Family Applications (2)

Application Number Title Priority Date Filing Date
ES009701017A Expired - Fee Related ES2125198B1 (es) 1997-05-13 1997-05-13 Asociacion a dosis fija de un inhibidor de la enzima convertidora de angiotensina y de un antagonista de los canales de calcio, procedimiento para su preparacion y su utilizacion para el tratamiento de enfermees cardiovasculares.
ES98500119T Expired - Lifetime ES2197443T3 (es) 1997-05-13 1998-05-12 Asociacion a dosis fijas de un inhibidor de la enzima convertidora de angiotensina y de un antagonista de los canales de calcio para el tratamiento de enfermedades cardiovasculares.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES98500119T Expired - Lifetime ES2197443T3 (es) 1997-05-13 1998-05-12 Asociacion a dosis fijas de un inhibidor de la enzima convertidora de angiotensina y de un antagonista de los canales de calcio para el tratamiento de enfermedades cardiovasculares.

Country Status (23)

Country Link
EP (1) EP0884054B9 (es)
JP (1) JP3576806B2 (es)
CN (1) CN1146418C (es)
AR (1) AR011730A1 (es)
AT (1) ATE236653T1 (es)
AU (1) AU735404B2 (es)
BR (1) BR9805597A (es)
CA (1) CA2234899C (es)
CZ (1) CZ292616B6 (es)
DE (1) DE69813083T2 (es)
DK (1) DK0884054T3 (es)
ES (2) ES2125198B1 (es)
HU (1) HUP9801075A3 (es)
IL (1) IL124253A (es)
NO (1) NO315545B1 (es)
NZ (1) NZ330447A (es)
PL (1) PL192117B1 (es)
PT (1) PT884054E (es)
RU (1) RU2182002C2 (es)
SK (1) SK284337B6 (es)
TR (1) TR199800847A3 (es)
TW (1) TW562679B (es)
ZA (1) ZA983806B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU226950B1 (en) * 1999-11-03 2010-03-29 Richter Gedeon Nyrt The magnesium salt of enalapril and antihypertensive pharmaceutical composition containing it
TWI246921B (en) * 2000-04-11 2006-01-11 Sankyo Co Stabilized pharmaceutical composition with calcium blocker
HU230253B1 (hu) * 2001-01-26 2015-11-30 Merck Sharp & Dohme Corp Peroxiszóma proliferátor-aktivált receptor (PPAR) aktivátor(ok) és szterin-abszorpció inhibitor(ok) kombinációi és alkalmazásuk vaszkuláris indikációk kezelésére
JP4633469B2 (ja) * 2002-12-16 2011-02-16 キッセイ薬品工業株式会社 経口固形医薬
RU2618471C2 (ru) * 2012-12-03 2017-05-03 Закрытое Акционерное Общество "Вертекс" Пероральная фармацевтическая композиция диуретика и ингибитора АПФ в микронизированной форме, лекарственное средство и его применение
CN109350733A (zh) * 2018-06-08 2019-02-19 山东理工职业学院 一种马来酸依那普利片剂的制备方法
CN109985013B (zh) * 2019-05-10 2021-08-10 河北君圣药业有限公司 一种尼群地平分散片及其制备方法
CN115501224A (zh) * 2022-10-09 2022-12-23 南昌大学第一附属医院 马来酸依那普利叶酸片联合通心络在制备治疗高血压合并颈动脉硬化药物的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0180785A1 (de) * 1984-10-17 1986-05-14 Bayer Ag Arzneimittel, enthaltend eine Kombination von Nitrendipin mit Enalapril, und Verfahren zu seiner Herstellung

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USH734H (en) * 1988-03-07 1990-02-06 E. R. Squibb & Sons, Inc. Method for inhibiting onset of or treating migraine headaches employing an ACE inhibitor
JPH01275529A (ja) * 1988-03-21 1989-11-06 E R Squibb & Sons Inc 晩発性運動障害の抑制治療剤
CA2007525A1 (en) * 1989-01-30 1990-07-30 Zola P. Horovitz Method for facilating dieting employing an ace inhibitor
US5160744A (en) * 1991-06-27 1992-11-03 Alza Corporation Verapmil therapy
US5246944A (en) * 1991-08-13 1993-09-21 Merck & Co., Inc. Quinoline angiotensin ii antagonists incorporating a substituted benzyl element
SI9111842A (sl) * 1991-11-25 1998-04-30 Krka Stabilna formulacija soli enalaprila, postopek za njeno pripravo in njena uporaba
SI9300504A (en) * 1993-09-28 1995-04-30 Krka Process for preparation solid dispersions and deposits of calcium antagonist dihidropyrimidine derivates and pharmaceutical compositions comprising the same
US5573780A (en) * 1995-08-04 1996-11-12 Apotex Usa Inc. Stable solid formulation of enalapril salt and process for preparation thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0180785A1 (de) * 1984-10-17 1986-05-14 Bayer Ag Arzneimittel, enthaltend eine Kombination von Nitrendipin mit Enalapril, und Verfahren zu seiner Herstellung

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, Vol. 102, Nr. 1, 7-Enero-1985, pagina 35, resumen 372X, Columbus, Ohio, US; M.E. VINCENT y col. "Hemodynamic and humoral responses to enalapril and nifedipine in the rat" & CLIN. EXP. HYPERTENS., PART A 1984, A6 (8), 1485-1497 *
J. CARDIOVASC. PHARMACOL. Vol. 12 (Suppl. 4), 1988; A. ZANCHETTI; "Nitrendipine und ACE Inhibitors". *
J. CARDIOVASC. PHARMACOL. Vol. 15, No 4, 1990; E. SCALBERT y col.; "Systemic and Regional Hemodynamic Interactions of Perindopril and Nitrendipine in the Spontaneously Hypertensive rat" *

Also Published As

Publication number Publication date
PL326246A1 (en) 1998-11-23
CA2234899C (en) 2004-08-10
SK61698A3 (en) 1998-12-02
EP0884054B9 (en) 2007-02-14
JPH11124330A (ja) 1999-05-11
CN1212869A (zh) 1999-04-07
ES2197443T3 (es) 2004-01-01
BR9805597A (pt) 2000-04-11
AR011730A1 (es) 2000-08-30
JP3576806B2 (ja) 2004-10-13
NO315545B1 (no) 2003-09-22
ES2125198B1 (es) 1999-11-16
HU9801075D0 (en) 1998-07-28
CA2234899A1 (en) 1998-11-13
EP0884054A2 (en) 1998-12-16
NO982112D0 (no) 1998-05-08
CZ138198A3 (cs) 1998-12-16
TR199800847A2 (xx) 1999-10-21
ATE236653T1 (de) 2003-04-15
HUP9801075A2 (hu) 1999-01-28
DE69813083T2 (de) 2004-05-27
PL192117B1 (pl) 2006-09-29
CN1146418C (zh) 2004-04-21
IL124253A (en) 2003-01-12
HUP9801075A3 (en) 2000-12-28
SK284337B6 (sk) 2005-02-04
NO982112L (no) 1998-11-16
EP0884054A3 (en) 2000-08-23
DE69813083D1 (de) 2003-05-15
AU6597398A (en) 1998-11-19
NZ330447A (en) 1998-12-23
TR199800847A3 (tr) 1999-10-21
TW562679B (en) 2003-11-21
PT884054E (pt) 2003-08-29
ZA983806B (en) 1999-02-19
AU735404B2 (en) 2001-07-05
EP0884054B1 (en) 2003-04-09
CZ292616B6 (cs) 2003-11-12
DK0884054T3 (da) 2003-07-21
RU2182002C2 (ru) 2002-05-10

Similar Documents

Publication Publication Date Title
PT893992E (pt) Formas de dosagem oral de desintegracao rapida
PT782449E (pt) Processo de fabrico de unidades de dosagem por granulacao humida
SE9703191D0 (sv) Medicament for improvement of duration of muscle function or treatment of muscle disorders or diseases
AU1079701A (en) Oral transmucosal drug dosage using solid solution
CA2396159A1 (en) Novel substituted benzimidazole dosage forms and method of using same
WO2002060384A3 (en) Pharmaceutical formulation
EP1685839B8 (en) Pharmaceutical oral dosage form comprising a combination of an opioid agonist and opioid antagonist
BR0003158A (pt) Formulação de dosagem oral de derretimentoinstantâneo
DE60022525D1 (de) Ramipril zur vorbeugung von kardiovaskulären vorfällen
DE3850823D1 (de) System zur Freisetzung von Medikamenten und dessen Herstellungsmethode.
EP0973507A4 (en) PHARMACEUTICAL FORM WHICH DELETES RAPID DISPERSION PROPERTIES, METHOD OF USE, AND METHOD FOR THE PRODUCTION THEREOF
WO2004069198A3 (en) Sugar-free oral transmucosal solid dosage forms and uses thereof
ES2125198A1 (es) Asociacion de dosis dija de un inhibidor de la enzima convertidora de angiotensina y de un antagonista de los canales de calcio, procedimiento para su preparacion y utilizacion para el tratamiento de enfermedades cardiovasculares.
AU7134898A (en) Biodegradable microparticles for the sustained delivery of therapeutic drugs
GB0201367D0 (en) Composition
RU98109345A (ru) Сочетание ингибитора ангиотензин-превращающего фермента и антагониста кальциевых каналов с фиксированной дозой, способ ее изготовления и применение для лечения сердечно-сосудистых заболеваний
ES2179729B1 (es) Forma farmaceutica solida de administracion oral dispersable en agua, que comprende rifampicina, isoniazida y piridoxina hidrocloruro, procedimiento para su obtencion y forma de presentacion de dicha forma farmaceutica.
FI961505A7 (fi) Uudet veren koaguloitumisjärjestelmässä terapeuttisesti aktiiviset pep tidiyhdisteet, menetelmä niiden valmistamiseksi ja niitä sisältävät fa rmaseuttiset koostumukset
EA200601283A1 (ru) Фармацевтическая композиция с контролируемым высвобождением, содержащая нерастворимый в кислотах полимер и биоадгезивный полимер
GB9917290D0 (en) Pharmaceutical composition
BR0202759A (pt) Composição farmacêutica de liberação modificada contendo bupropiona como substância ativa
Joshi et al. Optimisation of orodispersible tablet of amlodepine, ramipril in fixed dose combination by using quality by design (QbD) approach
RU96111879A (ru) Способ приготовления гомеопатических мягких лекарственных форм
WO2003045416A3 (de) Antiphlogistisches mittel und dessen verwendung
Ng et al. Case report on recombinant coagulation factor VIIa in the treatment of three haemophilia A patients with inhibitors in Singapore

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 19990216

Kind code of ref document: A1

Effective date: 19990216

PC2A Transfer of patent
PC2A Transfer of patent

Owner name: FERRER INTERNACIONAL, S.A.

Effective date: 20110525

FD2A Announcement of lapse in spain

Effective date: 20170825